Abstract 4904
Background
Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression in NS have the potential to provide novel targets for drug development. We hypothesized that there will be a difference in genomic profile of mUC in NS vs PCS.
Methods
Tumour tissue undergoing comprehensive genomic profiling (CGP) from patients with mUC were included from NS and age matched PCS within the same time period (2014-19). Clinical and CGP data were retrospectively collected. CGP was performed using FoundationOne (Foundation Medicine, Cambridge, MA), which provides exonic coverage of 315 genes.
Results
See table.Table:
943P
Non-smoker | Smoker | P value | |
---|---|---|---|
Median age at diagnosis, years (range) | 66.5 (33-86) | 67 (35-85) | 0.94 |
Site of primary | 0.009 | ||
Bladder | 37 (80%) | 39 (100%) | |
Upper tract | 9 (19.6%) | 0 | |
Urethral | 1 (<1%) | 0 | |
Gender | 0.001 | ||
Male | 32 | 38 | |
Female | 14 | 1 | |
Median number of genomic alterations (range) | 7 (1-17) | 7 (1-18) | 0.26 |
MLL2 gene alteration | 11 | 1 | 0.01 |
Conclusions
While the overall number of genomic alteration per patient and alteration frequencies were similar in NS vs PCS, we found a significantly higher frequency of MLL2 alterations in NS (p < 0.05). This finding is in agreement with previous reports of MLL2 alterations in UC; however, its significantly higher prevalence in NS is a novel finding and may suggest different oncogenic pathways in NS. It’s interesting to note that MLL2 alterations have been reported as drivers of self-renewal in bladder cancer stem cells (Yang et al, Euro Urol 2017, PMID 27387124).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Huntsman Cancer Institute.
Funding
Has not received any funding.
Disclosure
B.L. Maughan: Advisory / Consultancy: Peloton Therapeutics; Advisory / Consultancy: BMS; Advisory / Consultancy: Tempus; Advisory / Consultancy: Bayer; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy: Astellas Pharma. N. Agarwal: Advisory / Consultancy: Astellas; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Argos; Honoraria (institution), Advisory / Consultancy: Bayer; Honoraria (institution), Advisory / Consultancy: Exelixis; Honoraria (institution), Advisory / Consultancy: Eisai; Honoraria (institution), Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Foundation One; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: Medivation; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Nektar; Honoraria (institution), Advisory / Consultancy: Genentech; Honoraria (institution), Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Pharmacyclics; Honoraria (institution): Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract
2888 - Development and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision
Presenter: Kuiyuan Liu
Session: Poster Display session 3
Resources:
Abstract
3607 - Deep learning in nasopharyngeal carcinoma: a retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging
Presenter: Meng Yun Qiang
Session: Poster Display session 3
Resources:
Abstract
5848 - Combined androgen blockade in patients with advanced androgen receptor–positive salivary gland carcinoma: Exploratory biomarker analyses
Presenter: Chihiro Fushimi
Session: Poster Display session 3
Resources:
Abstract
4484 - Classification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape
Presenter: Russell Madison
Session: Poster Display session 3
Resources:
Abstract
5753 - Trastuzumab plus docetaxel in patients with advanced HER2–positive salivary duct carcinoma: Exploratory biomarker analyses
Presenter: Hideaki Takahashi
Session: Poster Display session 3
Resources:
Abstract
3373 - Development and characterization of salivary gland cancer organoid cultures
Presenter: Wim Boxtel
Session: Poster Display session 3
Resources:
Abstract
3118 - A parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity
Presenter: Ekaterina Alekseeva
Session: Poster Display session 3
Resources:
Abstract
4512 - The humanistic burden reported by patients diagnosed with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) in Europe
Presenter: Prianka Singh
Session: Poster Display session 3
Resources:
Abstract
3961 - Concurrent Chemotherapy and External Radiation Therapy: An Open Label Non-Inferiority Phase III Randomized Controlled Trial of Weekly versus Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: CONCERT trial
Presenter: ATUL SHARMA
Session: Poster Display session 3
Resources:
Abstract